Raymond James Financial’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$66.3M Sell
224,790
-31,989
-12% -$8.43M 0.02% 770
2026
Q2
$58.2M Buy
256,779
+63,247
+33% +$11.3M 0.02% 855
2026
Q1
$33.4M Buy
193,532
+71,278
+58% +$13.2M 0.01% 1125
2025
Q4
$24.4M Buy
122,254
+99,976
+449% +$18.1M 0.01% 1303
2025
Q3
$3.49M Sell
22,278
-3,084
-12% -$490K ﹤0.01% 2738
2025
Q2
$3.85M Sell
25,362
-197,597
-89% -$26.3M ﹤0.01% 2553
2025
Q1
$33.6M Sell
222,959
-8,761
-4% -$1.47M 0.01% 956
2024
Q4
$42.8M Hold
231,720
– – 0.02% 810

Other funds holding CRL

Raymond James Financial's CRL Position: Q3 2026 in Review

Raymond James Financial reduced its Charles River Laboratories (CRL) stake by 12% in Q3 2026, selling an estimated $8.43M and leaving 224,790 shares worth $66.3M. The position accounts for 0.02% of the portfolio, ranked #770.

Raymond James Financial first reported a position in CRL in Q4 2024 and has held it in 8 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Raymond James Financial held 224,790 shares of Charles River Laboratories worth $66.3M as of Q3 2026.
  • Raymond James Financial sold 31,989 Charles River Laboratories shares in Q3 2026, an estimated $8.43M.
  • Charles River Laboratories made up 0.02% of Raymond James Financial's portfolio in Q3 2026, its #770 holding.
  • Raymond James Financial first reported a position in Charles River Laboratories in Q4 2024 and has held it in 8 quarters since.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.